SH1573 / Nanjing Sanhome Pharma - LARVOL DELTA

Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China. (PubMed, Acta Pharm Sin B) - "This research successfully promoted the approval of SH1573 for clinical trials (CTR20200247). All experiments demonstrated that, as a potential drug against mIDH2 R140Q acute myeloid leukaemia, SH1573 was effective and safe."

Journal • Preclinical • Acute Myelogenous Leukemia • Breast Cancer • Cardiovascular • Hematological Malignancies • Leukemia • Oncology • Solid Tumor

A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia (clinicaltrials.gov) - P1; N=41; Recruiting; Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.

Clinical • New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology